Trial reportObesity (Silver Spring, Md.)2025
β-alanine supplementation in adults with overweight and obesity: a randomized controlled feasibility trial.
Trial report in Obesity (Silver Spring, Md.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- β-alanine supplementation in adults with overweight and obesity: a randomized controlled feasibility trial.Obesity (Silver Spring, Md.) · 2025Trial
- Carnosine-Related Metabolism in Rat Cardiomyocytes and Human Heart Tissue.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- The impact of sports supplements on metabolism, glycemic control, and lipid profile in adolescents and young adults: a narrative review.Pediatric endocrinology, diabetes, and metabolism · 2026Review
- p16INK4a Deletion Alleviated Obesity-Associated Kidney Fibrosis by Regulating Metabolic Reprogramming and the Inflammasome Pathway.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveOverweight and obesity are characterized by excess adiposity and systemic, chronic, low-grade inflammation, which is associated with several metabolic disorders. The aim of this study was to assess the feasibility and tolerability of β-alanine supplementation and to explore the effects on cardiometabolic health and cardiovascular, hepatic, and renal function in adults with overweight and obesity.
methodsA total of 27 adults (44% female; mean [SD], age: 58 [10] years, BMI: 31.1 [2.9] kg/m
resultsβ-alanine was well tolerated and adhered to (adherence: placebo, 0.91 [95% CrI: 0.84-0.95]; β-alanine, 0.92 [95% CrI: 0.85-0.95]), and side effects remained at or below baseline throughout. The probability that β-alanine supplementation affected cardiometabolic, cardiovascular, or clinical biochemical outcomes was low.
conclusionsSustained-release β-alanine supplementation is well tolerated and adhered to in adults with overweight and obesity. Future research should consider more advanced metabolic conditions, which may benefit from longer duration supplementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.